Brandt J T, Stephens R E, Hinkle G H
Department of Pathology, Ohio State University, Columbus 43210.
Thromb Res. 1988 Jul 15;51(2):187-96. doi: 10.1016/0049-3848(88)90062-x.
Recent evidence suggests that heparan sulfate on endothelial cell surfaces acts as a catalyst for the neutralization of thrombin by antithrombin III (AT III). Fibroblasts also produce heparan sulfate which is present on the cell surface and secreted into the extracellular matrix. We evaluated the ability of cultured human fibroblasts to catalyze the interaction between thrombin and AT III and found that heparan sulfate produced by post-confluent fibroblasts was anticoagulantly active. Furthermore, after initial binding of thrombin to cells, thrombin-heparan sulfate appeared in the fluid phase above the cells; this thrombin could be rapidly neutralized by AT III independent of the further presence of cells. These results indicate that fibroblasts do produce an anticoagulantly active species of heparan sulfate and that the normal interaction between AT III and thrombin may be driven by initial release of heparan sulfate from the cell surface by thrombin followed by AT III interaction with the soluble thrombin-heparan sulfate complex.
最近有证据表明,内皮细胞表面的硫酸乙酰肝素可作为抗凝血酶III(AT III)中和凝血酶的催化剂。成纤维细胞也会产生硫酸乙酰肝素,其存在于细胞表面并分泌到细胞外基质中。我们评估了培养的人成纤维细胞催化凝血酶与AT III相互作用的能力,发现汇合后成纤维细胞产生的硫酸乙酰肝素具有抗凝活性。此外,凝血酶与细胞初步结合后,凝血酶-硫酸乙酰肝素出现在细胞上方的液相中;这种凝血酶可被AT III迅速中和,而与细胞的进一步存在无关。这些结果表明,成纤维细胞确实产生了具有抗凝活性的硫酸乙酰肝素,并且AT III与凝血酶之间的正常相互作用可能是由凝血酶最初从细胞表面释放硫酸乙酰肝素,随后AT III与可溶性凝血酶-硫酸乙酰肝素复合物相互作用所驱动的。